Recent Breakthroughs in the Treatment of Alzheimer Disease

Expert neurologists, Richard S. Isaacson, MD, and Marc E. Agronin, MD, describe the journey to the FDA approval of aducanumab for the treatment of Alzheimer disease and what this means for clinicians.

The importance of the ongoing EMBARK phase III clinical trial and the collection of real-world data on the use of aducanumab is discussed.

The challenges of identifying the appropriate patient, earlier in the disease course, for treatment with aducanumab for Alzheimer disease.

Impact of the approval of aducanumab on the treatment landscape and other drugs in development for the treatment of Alzheimer disease.

The use of blood-based biomarkers for diagnosis of Alzheimer disease in the context of the comprehensive diagnosis. 

Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.